Express Pharma

VWR enters into definitive agreement with Avantor

3

The agreement will create a vertically integrated, global player in manufacturing and supply chain solutions for the life sciences, advanced technologies, and research industries

Avantor, a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries, and VWR, the global independent provider of product, supply chain, and service solutions to laboratory and production customers, have entered into a definitive agreement under which Avantor will acquire VWR for $33.25 in cash per share of VWR common stock, reflecting an enterprise value of approximately $6.4 billion.

Avantor’s acquisition of VWR will create a major consumables-focussed solutions and services provider to the high-growth life sciences and advanced technologies industries, as well as education, government, and research institutions across the globe. The acquisition will build on each company’s strengths, including Avantor’s cGMP manufacturing processes, significant exposure to emerging markets and VWR’s significant position across the Americas and Europe. The combined company will be a vertically integrated organisation, serving a global customer base in all areas of their activities, from research through production – a unique advantage in a fast growing marketplace.

 

Comments are closed.